Bladder cancer is the ninth most common cancer globally, and for patients with advanced or aggressive forms, the standard treatment has been brutal: surgical removal of the entire bladder, followed by a lifetime of urostomy bags and the daily indignities that come with externalised bodily function. A phase-two trial led by the Institute of Cancer Research, London, now suggests that default may be ready to change. The trial tested durvalumab — a PD-L1 inhibitor made by AstraZeneca — added to the existing combination of chemotherapy and radiotherapy in 54 patients with aggressive bladder cancer. The results, presented at the American Society of Clinical Oncology's annual meeting in Chicago: cancer did not return in 46 of 54 patients, an 85% non-recurrence rate. The prior standard — chemoradiation without immunotherapy — achieved 60% in earlier trials. That is a 25-percentage-point improvement in the headline metric, and critically, none of the 54 patients underwent radical cystectomy. The mechanism is well-understood immunology. Durvalumab blocks PD-L1, a protein that cancer cells exploit to hide from immune detection. Strip the cloak, and the immune system can find and destroy what chemotherapy and radiation have weakened. This builds on work by the same team dating to 2012, when Nick James's group at the ICR demonstrated that adding low-cost chemotherapy to radiotherapy improved long-term bladder cancer outcomes — a finding that itself changed standard practice. The human stakes are concrete. Artist Tracey Emin, diagnosed with aggressive bladder cancer in 2020, described life after radical cystectomy in unsparing terms: a urostomy bag that leaks, the social anxiety of public incontinence, the loss of bodily privacy. For the roughly 600,000 people diagnosed with bladder cancer worldwide each year, the prospect of keeping their organ intact while improving survival odds is not incremental — it is qualitatively different. The caveats are real and worth stating plainly. This is a phase-two trial with 54 patients and roughly one year of follow-up. Phase-two trials establish signal, not proof. The 85% figure needs validation in a larger, longer phase-three trial before it can change clinical guidelines. Michelle Mitchell of Cancer Research UK, who was not involved in the study, made this point directly: further research at larger scale is needed. The funding structure matters. AstraZeneca funded the trial and manufactures durvalumab. This does not invalidate the results — most oncology trials are industry-funded — but it does mean the commercial incentive and the scientific question are aligned in a way that demands independent replication. Durvalumab is already approved for other cancers; extending its indication to bladder-sparing treatment would be commercially significant for AstraZeneca. If the phase-three results hold, the downstream effects ripple through healthcare systems: fewer radical surgeries, shorter hospital stays, lower rehabilitation costs, reduced long-term care for urostomy management, and a population of bladder cancer survivors who retain organ function and independence. The ICR's Prof Kristian Helin framed the priority as "smarter, kinder treatments" — and on this trial's evidence, the combination of immunotherapy with chemoradiation delivers both.